Who
Robert Charles Jahr
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Outlook Therapeutics.
In numbers
- Trades disclosed
- 7
- Buys
- 1
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Jul 2025
- Last trade
- 14 Aug 2026
- Last filed
- 14 Aug 2026
Companies traded
Activity over time
1 Aug – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Aug 2026filed 14 Aug 2026 | OTLK Outlook TherapeuticsBiotechnology | SEC FORM 4 Bought | —151,515 | filing |
| 14 Aug 2026filed 14 Aug 2026 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —151,515 | filing |
| 14 Aug 2026filed 14 Aug 2026 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —151,515 | filing |
| 14 Aug 2026filed 14 Aug 2026 | OTLK Outlook TherapeuticsBiotechnology | SEC FORM 4 Bought | —151,515 | filing |
| 21 Jul 2026filed 23 Jul 2026 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 21 Jul 2026filed 23 Jul 2026 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 1 Jul 2025filed 9 Jul 2025 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —800,000 at $0.00 | filing |
News
Reviewing Aprea Therapeutics (NASDAQ:APRE) & Oncobiologics (NASDAQ:OTLK)OTLK · themarketsdaily.com · 20 Oct 2026
0 headlines in the last 90 days name Robert Charles Jahr; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.